1.The Avon Patellofemoral Joint Replacement: Mid-Term Prospective Results from an Independent Centre.
Pouya AKHBARI ; Tamer MALAK ; Sebastian DAWSON-BOWLING ; Debra EAST ; Kim MILES ; P Adrian BUTLER-MANUEL
Clinics in Orthopedic Surgery 2015;7(2):171-176
BACKGROUND: Approximately 10% of patients with osteoarthritis (OA) of the knee have unicompartmental OA confined to the patellofemoral joint (PFJ). The main surgical options are total knee replacement (TKR) and PFJ replacement (PFJR). PFJR has a number of advantages over TKR, including being less invasive, preserving the unaffected parts of the knee, allowing faster recovery and better range of motion and function. We report our prospective mid-term results of the Avon PFJR for established isolated PFJ arthritis in 61 consecutive procedures. METHODS: Sixty-one Avon PFJRs were performed in 57 patients. The outcome measures were the new Oxford knee score (OKS), Hungerford and Kenna score (HKS), and Crosby Insall knee scores. Only patients with severe isolated PFJ OA were included. The diagnosis was based on a combination of clinical, radiological and, where available, arthroscopic findings. RESULTS: Mean follow-up was 5.09 years (range, 12 to 124 years). There were 2 revisions in the first 5 years. The median HKS score was 80 (interquartile range, 70 to 95) and the mean OKS was 31.8 (+/- standard deviation, 8.7) at 5 years. These were significantly better (p < 0.001) than the preoperative scores. CONCLUSIONS: The Avon prosthesis gives good functional outcomes in the medium term and survives well. Our data support other studies in the literature and is the largest independent prospective study to date.
Aged
;
*Arthroplasty, Replacement, Knee
;
Female
;
Humans
;
Male
;
Patellofemoral Joint/*surgery
;
Prospective Studies
;
Time Factors
;
Treatment Outcome
2.Recombinant human zona pellucida proteins ZP1, ZP2 and ZP3 co-expressed in a human cell line.
Mirjana MARTIC ; Eric K MOSES ; Tim E ADAMS ; De Yi LIU ; Debra A GOOK ; Claire GARRETT ; Marjorie E DUNLOP ; Gordon H W BAKER
Asian Journal of Andrology 2004;6(1):3-13
AIMTo produce biologically active recombinant human (rh) ZP proteins in a human cell for use in sperm function tests.
METHODSThe human embryonic kidney cell line 293T was employed to produce rhZP1, rhZP2 and rhZP3 proteins individually and together by co-expression. Presence of these proteins in the culture medium and cell lysate was assessed by Western blotting analysis. The effect of the recombinant proteins on the human AR was assessed.
RESULTSRhZP2 and rhZP3 were secreted into the culture medium, whereas rhZP1 was found only in the cell lysate. Interestingly, when all zona pellucida proteins were co-expressed in the same cells, rhZP1 was also secreted into the culture medium. However, despite the presence of all three ZP proteins in sufficient concentration and evidence of heavy glycosylation on gel electrophoresis, biological activity to induce the AR was not observed.
CONCLUSIONRhZP1, rhZP2 and rhZP3 were successfully expressed in the human embryonic kidney cell line 293T. It appears that an interaction amongst these proteins may be required for release of rhZP1 from the cell. Although this approach is not satisfactory for producing active human ZP proteins, it makes a significant contribution to the understanding of the structural and functional characteristics of the ZP proteins.
Acrosome Reaction ; drug effects ; Blotting, Western ; Cell Line ; Egg Proteins ; analysis ; genetics ; pharmacology ; Embryo, Mammalian ; Female ; Fluorescent Antibody Technique ; Gene Expression ; Glycoside Hydrolases ; metabolism ; Glycosylation ; Humans ; Kidney ; Male ; Membrane Glycoproteins ; analysis ; genetics ; pharmacology ; Receptors, Cell Surface ; analysis ; genetics ; Recombinant Proteins ; analysis ; pharmacology ; Zona Pellucida Glycoproteins